Stephen Squinto, Ph.D.

Executive Chairman

Dr. Stephen Squinto is an entrepreneur and biotechnology industry veteran with more than 30 years of experience in drug development. He currently serves as chief investment officer and managing partner of J.P Morgan Life Sciences Private Capital. He previously was an executive partner at OrbiMed Advisors, and served as interim chief executive officer at Passage … Read more

Bradley Campbell

Bradley Campbell is president and chief executive officer of Amicus Therapeutics and is also a member of its Board of Directors. Mr. Campbell joined Amicus in 2006 and led the global organization responsible for the commercialization of Galafold®. He also oversaw the corporate development, technical operations, market access, program management, clinical operations, and regulatory affairs … Read more

Craig Gordon, M.D.

Craig D. Gordon, M.D., is the founder of GordonMD Global, a private and public long-biased global biopharmaceutical investment firm. Prior to establishing his own firm, he was an Equity Investment Analyst at The Capital Group for over ten years with research and investment responsibilities for U.S. and Japanese biotechnology and pharmaceutical companies. Before joining Capital, he … Read more

Julie Hambleton, M.D.

Dr. Julie Hambleton is a biotechnology and pharmaceutical executive with over 20 years of experience leading oncology companies. Most recently she served as interim chief executive officer at Arch Oncology. Previously, she served as senior vice president, chief medical officer and head of development at IDEAYA Biosciences. Prior to her role at IDEAYA, she held … Read more

Gary Sender

Gary Sender is a seasoned executive and board member with more than 25 years of financial leadership experience in organizations ranging from large, multi-national pharmaceutical firms to early-stage biotechnology companies. He was chief financial officer of Nabriva Therapeutics plc, a publicly traded biopharmaceutical company, from 2016 until March 2021 when he retired. Prior to Nabriva, … Read more

Peter Thompson, M.D.

Dr. Peter Thompson is a member at OrbiMed Advisors LLC, an investment firm. Dr. Thompson currently serves on the boards of directors of Alpine Immune Sciences Inc., Corvus Pharmaceuticals, Inc., Decibel Therapeutics, Inc., Edgewise Therapeutics, Inc., Janux Therapeutics, Inc., and Silverback Therapeutics, Inc., as well as several private companies. Previously, Dr. Thompson served on the … Read more

Chris Duke

Interim Chief Executive Officer

Mr. Duke is an accomplished biotech executive with more than 20 years of global commercial, operational and clinical development experience at several leading rare disease and immuno-oncology companies. Mr. Duke previously served as chief operating officer of Gennao since its inception in 2020 and helped establish and led key corporate functions, including program management, manufacturing, … Read more

Anuj Goswami, J.D., MBA

General Counsel

Mr. Goswami joins the Gennao team with over 20 years of experience in private practice at Ballard Spahr LLP in Philadelphia. As a partner in Ballard’s Business & Finance practice, he has served numerous clients through various stages of the growth cycle, leading multi-disciplinary teams to support early stage to public companies. Mr. Goswami brings … Read more

Dale L. Ludwig, Ph.D.

Chief Scientific Officer

Dr. Ludwig is a recognized leader in the biopharmaceutical industry, having supported the development and successful launch of several biologic oncology products including Erbitux®, Cyramza™, Portrazza®, and Lartruvo™, as well as the clinical advancement of a number of other therapeutic antibodies over the course of his career. Most recently, he served as the chief science and … Read more

Joe McIntosh, M.D.

Chief Medical Officer

Dr. McIntosh joins Gennao with more than 16 years of drug development experience in the biopharmaceutical industry, with a focus on gene therapies and rare genetic disease. Previously, he served as chief medical officer for Jaguar Gene Therapy, responsible for the development of the company’s AAV9-based gene therapies. Prior to Jaguar, he served as chief … Read more